EIF2A Antibody

Overview

The initiation of protein synthesis in eukaryotic cells is regulated by interactions between protein initiation factors and RNA molecules. The eukaryotic initiation complex is composed of three subunits, designated eIF2a, eIF2b and eIF2g (eukaryotic translation initiation factor 2 a, band g, respectively), all of which work in concert to form a ternary complex with GTP and tRNA in the early stages of protein synthesis. eIF2a, also known as EIF2S1 or EIF2, is a 315 amino acid subunit of the eukaryotic initiation complex that functions to bind tRNA to the 40S ribosomal subunit (in a GTP-dependent manner), thereby initiating translation. In addition, the phosphorylation state of eIF2a controls the rate of tRNA translation. When eIF2a is not phosphorylated, translation occurs at a normal rate. However, upon phosphorylation by one of several kinases, eIF2a is stabilized, thus preventing the GDP/GTP exchange reaction and slowing translation.

This anti-EIF2A antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone PCRP-EIF2S1-1E2, Mouse IgG1, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: EIF2A
• Format: Purified
• Localization: Cytoplasm
• Species reactivity: Human
• Applications (listed): FACS, IF, WB
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone PCRP-EIF2S1-1E2, Mouse IgG1

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

EIF2A is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling EIF2A expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link EIF2A signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• FACS
• IF
• WB

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.